Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Long-Term Debt Repayments (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 16 years of Long-Term Debt Repayments data on record, last reported at $231000.0 in Q2 2025.

  • For Q2 2025, Long-Term Debt Repayments changed 0.43% year-over-year to $231000.0; the TTM value through May 2025 reached $930000.0, up 30.25%, while the annual FY2025 figure was $930000.0, 30.25% up from the prior year.
  • Long-Term Debt Repayments reached $231000.0 in Q2 2025 per LFCR's latest filing, down from $313000.0 in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $120.5 million in Q2 2023 and bottomed at -$29.5 million in Q4 2024.
  • Average Long-Term Debt Repayments over 5 years is $18.0 million, with a median of $232000.0 recorded in 2024.
  • Peak YoY movement for Long-Term Debt Repayments: surged 344160.0% in 2023, then plummeted 15397.41% in 2024.
  • A 5-year view of Long-Term Debt Repayments shows it stood at $38000.0 in 2021, then rose by 28.95% to $49000.0 in 2022, then skyrocketed by 293.88% to $193000.0 in 2023, then tumbled by 15397.41% to -$29.5 million in 2024, then skyrocketed by 100.78% to $231000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Long-Term Debt Repayments were $231000.0 in Q2 2025, $313000.0 in Q1 2025, and -$29.5 million in Q4 2024.